If approved in RCC, fruquintinib will be available for three indications, including endometrial and colorectal cancer.
After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...
CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today presented compelling primary results from the ...
In a readout of data from the phase 2 BNT111-01 trial (NCT04526899) presented at the 2025 European Society for Medical ...
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi ...
NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death Data Reinforces Mechanism of Action along with Efficacy and Safety Profile ...
NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients Latest Data Cut-Off Shows ...
NuCana (NCNA) presented data at the European Society for Medical Oncology Congress 2025, ESMO, on a new model system investigating the synergistic ...
A study published in Cancer Discovery finds that combining an epigenetic therapy with an anti-PD-1 antibody, which uses the ...
Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, ...